Bausch + Lomb Corporation Common Shares (BLCO)

FairStock Score: 45/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking at a large eye-health franchise that sells contact lenses, pharmaceuticals, and surgical products. Revenue has grown from $4.1B in fiscal year 2023 to $4.8B in fiscal year 2024 and $5.1B in fiscal year 2025, so the top line is moving in the right direction. But the company is not yet profitable: net income was -$260M in fiscal year 2023, -$317M in fiscal year 2024, and -$360M in fiscal year 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.4B but net income was still -$14M, with diluted EPS of -$0.04. That is better than fiscal Q1 2026, the quarter ended 2026-03-31, when net income was -$71M, and fiscal Q2 2025, the quarter ended 2025-06-30, when it was -$62M, so a turnaround may be forming. FairStock calls it a TURNAROUND because of a loss in the latest year after earlier profits. Financial health is the weak spot: debt-to-equity is 0.79, Altman Z-Score is 0.57, ROE is -2.52%, and ROCE is only 1.83%. Free cash flow is positive at $137M, but the FCF yield is just 2.4%. At $15.81 on 2026-10-13, P/B is 0.87, which offers some asset support, while negative P/E of -32.94, EV/EBITDA of 14.14, and FairStock Score 45/100 do not scream bargain. Piotroski is 6/9, suggesting some stabilization. The eye-health brands and installed base could be a moat, but until profits and returns improve, I would need more evidence.

In plain English: Bausch + Lomb makes eye-health products, including contact lenses, eye medicines, and surgical equipment. Sales are growing, but the company is still losing money and carries a fair amount of debt. At $15.81 on 2026-10-13, the shares look closer to cheap against the company's net assets, though the losses make the overall picture mixed rather than clearly strong or clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer